NVS Stock Recent News
NVS LATEST HEADLINES
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs.
The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday.
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer.
The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer drug launches. Novartis raised the 2024 core operating income guidance. Our buy rating is then confirmed.
On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year, primarily due to strong sales of its oncology franchise. So, Kisqali sales amounted to $717 million for the three months ended June 30, 2024, an increase of 45.4% year-on-year.
Novartis NYSE: NVS is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024.
Vasant Narasimhan, Novartis CEO, joins CNBC's Angelica Peebles on 'The Exchange' to discuss Q2 earnings, reception of its prostate cancer drug, and more.
Drugmaker Novartis' second-quarter results were better than expected. Profit guidance for the remainder of the year was also raised.
Novartis (NVS) American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidance.